<DOC>
	<DOCNO>NCT00964002</DOCNO>
	<brief_summary>RATIONALE : Efavirenz may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well efavirenz work treat patient metastatic prostate cancer .</brief_summary>
	<brief_title>Efavirenz Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess effect efavirenz non-PSA progression rate 3 month patient castration-refractory metastatic prostate cancer . Secondary - To assess effect efavirenz PSA response 3 month . - To assess effect efavirenz overall survival . - To assess effect efavirenz PSA progression-free survival . - To assess effect efavirenz symptomatic progression-free survival . - To assess tolerability safety profile efavirenz . OUTLINE : This multicenter study . Patients receive oral efavirenz daily absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer Metastatic disease Castrationrefractory disease No clinical symptom related disease progression PATIENT CHARACTERISTICS : WHO performance status 02 PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>